Evidence map›Paper›PMID 40635087›Full record

ArticleActa neuropathologica communications2025

Frontotemporal Lobar degeneration with TDP-43 presenting as progressive supranuclear palsy syndrome.

Aya Murakami, Shunsuke Koga, Hiroaki Sekiya, Masataka Nakamura, Yusuke Yakushiji, Dennis W Dickson

Abstract read
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aya MurakamiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Shunsuke KogaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. shunsuke.koga@pennmedicine.upenn.edu.
Hiroaki SekiyaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Masataka NakamuraDepartment of Neurology, Kansai Medical University, Osaka, Japan.
Yusuke YakushijiDepartment of Neurology, Kansai Medical University, Osaka, Japan.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. dickson.dennis@mayo.edu.

Funding

FAIN U19AG063911NIH grants P30-AG062677NIH grants U54-NS100693NIH GRANTS P01-AG03949NIH GRANTS R01-AG062348NIH GRANTS R01-NS121125NIH GRANTS RF1-NS123052
6 · The paper itself

Abstract

objectiveFrontotemporal lobar degeneration with TDP-43 pathology (FTLD) usually presents with frontotemporal dementia, semantic aphasia or progressive nonfluent aphasia. Corticobasal syndrome and atypical parkinsonism have been occasionally reported, but progressive supranuclear palsy (PSP) syndrome (also known as Richardson syndrome (RS)) has not been reported in patients with FTLD-TDP. In this study we report clinical and pathologic characteristics of FTLD-TDP, clinically diagnosed as PSP syndrome (FTLD-TDP-PSP).

methodsWe reviewed clinical information of 270 patients with FTLD-TDP from the Mayo Clinic brain bank and identified 5 patients with FTLD-TDP-PSP. As a control group, we selected ten consecutive patients of pathologically confirmed PSP with clinical presentations of PSP syndrome (PSP-RS). We compared the clinical and pathological features of FTLD-TDP-PSP and PSP-RS.

resultsThe most common clinical symptoms in FTLD-TDP-PSP were memory loss (100%) followed by parkinsonism (80%), early falls (60%), and behavioral variant FTD (60%). All patients with PSP-RS met the Movement Disorder Society's criteria for probable PSP, while only one FTLD-TDP-PSP met the probable PSP. Two of the five patients with FTLD-TDP-PSP had moderate or severe neuronal loss in the substantia nigra and one had moderate or severe neuronal loss in the putamen and globus pallidus.

conclusionA small subset of patients with FTLD-TDP can, in rare instances, present with symptoms associated with PSP. Therefore, FTLD-TDP may be considered in differential diagnosis, especially in patients who do not meet the diagnostic criteria. Our findings emphasize the need for further clinical and biomarker studies of FTLD-TDP.

Indexed as

DNA-Binding ProteinsFrontotemporal Lobar DegenerationSupranuclear Palsy, ProgressiveAgedAged, 80 and overBrainDiagnosis, DifferentialFemaleHumansMaleMiddle AgedDNA-Binding ProteinsTARDBP protein, humanFrontotemporal Lobar degenerationProgressive supranuclear palsyTDP-43

Identifiers

PMID40635087
PMCPMC12239482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.